- Closed registered direct offering for aggregate gross proceeds of US$175 million (the “Registered Direct Offering”) led by a syndicate of prominent biopharmaceutical institutional investors - - On ...
CARVYKTI ® (ciltacabtagene autoleucel; cilta-cel) net trade sales of approximately $524 million EC and U.S. FDA label updates for CARVYKTI ® to include overall survival benefit versus standard of care ...
– Successful outcome from FDA meeting on ALTO-207 in treatment-resistant depression; on track to initiate Phase 2b trial in the first half of 2026 and Phase 3 trial by early 2027 – – Positive blinded ...
View source version on businesswire.com: https://www.businesswire.com/news/home/20251112188096/en/ The articles, information, and content displayed on this webpage ...
– FREEDOM-DM1 15 mg/kg cohort demonstrated the highest mean splicing correction reported to date in DM1 patients – – FREEDOM2-DM1 5 mg/kg cohort on track to readout in Q1 2026, with all patients ...
– Topline data for Phase 2 trials of ALTO-101 in CIAS expected 1Q 2026 and ALTO-300 in MDD expected mid-2026 – – Closed $50 million PIPE; strong cash position of $184.2 million as of October 31 ...
Last term, Drexel University faculty members were recognized for their scholarly research and prolific academic and professional contributions. This update offers a snapshot of activity courtesy of ...
Aimco to Seek Shareholder Approval to Adopt Plan of Sale and Liquidation, Estimates Liquidating Distributions of Between $5.75 and $7.10 Per Share. DENVER, Nov. 10, 2025 /PRNewswire/ -- Apartment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback